JP2009544574A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544574A5
JP2009544574A5 JP2009516592A JP2009516592A JP2009544574A5 JP 2009544574 A5 JP2009544574 A5 JP 2009544574A5 JP 2009516592 A JP2009516592 A JP 2009516592A JP 2009516592 A JP2009516592 A JP 2009516592A JP 2009544574 A5 JP2009544574 A5 JP 2009544574A5
Authority
JP
Japan
Prior art keywords
antibody
use according
fragment
mab
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009516592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/014712 external-priority patent/WO2007149586A2/en
Publication of JP2009544574A publication Critical patent/JP2009544574A/ja
Publication of JP2009544574A5 publication Critical patent/JP2009544574A5/ja
Pending legal-status Critical Current

Links

JP2009516592A 2006-06-22 2007-06-22 癌を処置するための抗c35抗体 Pending JP2009544574A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81556206P 2006-06-22 2006-06-22
PCT/US2007/014712 WO2007149586A2 (en) 2006-06-22 2007-06-22 Anti-c35 antibodies for treating cancer

Publications (2)

Publication Number Publication Date
JP2009544574A JP2009544574A (ja) 2009-12-17
JP2009544574A5 true JP2009544574A5 (enExample) 2011-08-25

Family

ID=38834165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516592A Pending JP2009544574A (ja) 2006-06-22 2007-06-22 癌を処置するための抗c35抗体

Country Status (7)

Country Link
US (1) US20080305111A1 (enExample)
EP (1) EP2029172A4 (enExample)
JP (1) JP2009544574A (enExample)
CN (1) CN101505793A (enExample)
AU (1) AU2007261247A1 (enExample)
CA (1) CA2656918A1 (enExample)
WO (1) WO2007149586A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
JP5690593B2 (ja) * 2007-12-26 2015-03-25 ヴァクシネックス, インコーポレイテッド 抗c35抗体併用療法および方法
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
EP3634459A4 (en) 2017-02-10 2021-01-06 Washington University ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5489425A (en) * 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
JP2831073B2 (ja) * 1988-06-24 1998-12-02 ザ ダウ ケミカル カンパニー 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
US5756065A (en) * 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
CN1033030C (zh) * 1988-06-24 1996-10-16 唐化学原料公司 大环双官能螯合剂及其配合物和抗体共轭物的制备方法
US5274119A (en) * 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5696239A (en) * 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5808003A (en) * 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
ES2284161T3 (es) * 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
IE921342A1 (en) * 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
US5428139A (en) * 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3720353B2 (ja) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US5935801A (en) * 1996-03-29 1999-08-10 Dana-Farber Cancer Institute Monoclonal antibody that detects apoptotic antigen
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
CA2413211A1 (en) * 2000-04-04 2001-10-11 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
CA2406378A1 (en) * 2000-04-12 2001-10-25 University Of Rochester Targeted vaccine delivery systems
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
IL161418A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2004037993A2 (en) * 2002-10-22 2004-05-06 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
CA2548180C (en) * 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Similar Documents

Publication Publication Date Title
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
ES2657970T3 (es) Anticuerpos contra ROR1 de conejo/ser humano quiméricos
ES2469369T3 (es) Anticuerpos anti-CXCR4 humanizados para el tratamiento del cáncer
ES2717908T3 (es) Anticuerpos S100A4 y usos terapéuticos de los mismos
EP3272772B1 (en) Use of an anti-ang2 antibody
HK1245802A1 (zh) 多特异性抗体、抗体类似物、组合物和方法
JP7711208B2 (ja) Dll3に対する結合分子及びその使用
JP2012521218A5 (enExample)
US9994632B2 (en) Humanized or affinity-matured anti Ang-2 antibody and uses thereof
IL255416B1 (en) Anti – cd71 antibodies, activatable anti – cd71 antibodies compositions comprising same and uses thereof
JP2011207882A5 (enExample)
JP7642096B2 (ja) 抗cntn4抗体及びその使用
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2014515600A5 (enExample)
JP2010500006A5 (enExample)
JP2018528759A5 (enExample)
JP2020522512A5 (enExample)
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2022546387A (ja) 細胞間接着分子1(icam1)抗体薬物抱合体およびそれらの使用
WO2024184349A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
KR20140019284A (ko) 항-C-Met 항체 및 이의 이용 방법들
US20220211846A1 (en) Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
CN118852437A (zh) Ror1特异性抗体及其应用
JP2025525408A (ja) 二重特異性抗体及びその応用
JP2018529716A (ja) 癌幹細胞を阻害する組成物及び方法